Insmed CEDAR Study Misses Endpoints in HS Trial
BRIDGEWATER, N.J., April 7, 2026 Insmed Incorporated has announced that its Phase 2b CEDAR clinical trial evaluating brensocatib in...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BRIDGEWATER, N.J., April 7, 2026 Insmed Incorporated has announced that its Phase 2b CEDAR clinical trial evaluating brensocatib in...
INDIANAPOLIS | January 7, 2026 — Eli Lilly and Company has announced an agreement to acquire Ventyx Biosciences, a...
